Clinical trial · Interventional
Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery
Intraductal Therapy of DCIS: A Presurgery Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This clinical trial is studying the side effects of doxorubicin hydrochloride liposome and to see how well it works in treating women with ductal carcinoma in situ undergoing surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (12)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| breast duct lavage | Procedure | — | UNRESOLVED |
| DNA methylation analysis | Genetic | — | UNRESOLVED |
| fluorescence in situ hybridization | Genetic | — | UNRESOLVED |
| immunoenzyme technique | Other | — | UNRESOLVED |
| immunohistochemistry staining method | Other | — | UNRESOLVED |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| loss of heterozygosity analysis | Genetic | — | UNRESOLVED |
| neoadjuvant therapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Efficacy
- measure
- Safety
- measure
- Ability to identify and cannulate the duct
- measure
- Integration of the Humboldt Community Breast Health Project into the planning and execution of this study
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of ductal breast carcinoma in situ by core needle biopsy * No pathological invasive or microinvasive disease in the affected breast * Mammographic microcalcifications are limited to one ductal system or one quadrant of breast * Hormone receptor status not specified PATIENT CHARACTERISTICS: * Menopausal status not specified * Must be able to undergo necessary surgery * Not pregnant PRIOR CONCURRENT THERAPY: * No prior surgery or radiotherapy to the recently diagnosed breast * More than 12 months since prior chemotherapy * No prior subareolar breast surgery to the affected breast * Not concurrently involved in a research protocol for unapproved new drug evaluation
References
Publications (0)
Data not yet available